TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15045133

Group type: EXPERIMENTAL
Intervention: Substitution of unfractionated heparin by low-molecular-weight heparins for regular anticoagulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antigen assays for confirmation of HIT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cut-off established in adults for antigen assays
Number of subjects: 12
Study: 11573534

Group type: EXPERIMENTAL
Intervention: Multiple small boluses of thiopental
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single bolus of thiopental
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infusion of thiopental
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 60
Study: 9778007

Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl and Propofol combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0
Study: 7785193

Group type: EXPERIMENTAL
Intervention: Subtotal irradiation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Polychemotherapy
Number of subjects: 15
Study: 3198983

Group type: EXPERIMENTAL
Intervention: Aminozolamide suspension
Number of subjects: 11

Group type: COMPARATOR
Intervention: Aminozolamide gel formulation
Number of subjects: 11
Study: 31815582

Group type: EXPERIMENTAL
Intervention: FOLFOX (platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FOLFOX (in patients with ERCC1 levels < 1.7)
Number of subjects: 202

Group type: COMPARATOR
Intervention: IT (non‐platinum‐containing regimen of irinotecan and docetaxel)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 202
Study: 29112801

Group type: EXPERIMENTAL
Intervention: Routine Assessment of Patient Index Data 3 (RAPID3)
Number of subjects: 0
Study: 28618297

Group type: EXPERIMENTAL
Intervention: Trained group (received communication strategies lecture)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untrained group (no communication strategies lecture)
Number of subjects: 38
Study: 26703661

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention with health coach-facilitated virtual visits and cloud-based glucose monitoring system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10
Study: 23508600

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study: 21393097

Group type: EXPERIMENTAL
Intervention: Intervention group (AEP scores available to physician)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intervention group (QOLIE-31 scores)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (QOLIE-31 scores)
Number of subjects: 102
Study: 18178063

Group type: EXPERIMENTAL
Intervention: Low glycemic load diet (25% energy from protein, 45% from low glycemic index carbohydrates)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control diet (carbohydrate-dense foods without reference to glycemic index)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Number of subjects: 31
Study: 16829707

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enalapril (5 mg once daily)
Number of subjects: 26
Study: 12809582

Group type: EXPERIMENTAL
Intervention: isoniazid for six months (6H)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: rifampin plus isoniazid for three months (3RH)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: rifampin plus pyrazinamide for two months (2RZ)
Number of subjects: 319

Group type: COMPARATOR
Intervention: no treatment (NT)
Number of subjects: 319
Study: 10819341

Group type: EXPERIMENTAL
Intervention: H. influenzae type b capsular polysaccharide‐tetanus protein conjugate vaccine
Number of subjects: 174
Study: 8888464

Group type: EXPERIMENTAL
Intervention: Empirically-derived social support intervention consisting of four standardized face-to-face sessions at two week intervals and telephone contact in the intervening weeks.
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 319
Study: 2001639

Group type: EXPERIMENTAL
Intervention: Acupuncture (points: Hegu, Neiguan, Zusanli and Gongsun bilaterally)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pretend acupuncture (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 36
Study: 6666217

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 22
Study: 31473690

Group type: EXPERIMENTAL
Intervention: Community engagement program utilizing resilience theory framework
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Risk-reduction measures (e.g., checking air-quality forecasts, limiting outside activities)
Number of subjects: 550
Study: 30076988

Group type: EXPERIMENTAL
Intervention: Lifestyle education, stress reduction guided imagery, and lifestyle behavior guided imagery (12-week intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 27422893

Group type: EXPERIMENTAL
Intervention: apremilast 20 mg BID
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 484

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 484
Study: 24647431

Group type: EXPERIMENTAL
Intervention: Pain (induced by hypertonic saline injection) during bilateral leg squat task
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition (no pain) during isometric tasks
Number of subjects: 15
Study: 22851808

Group type: EXPERIMENTAL
Intervention: Phase-delayed sleep regimen (23:00 to 07:00)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Customary sleep regimen (20:30 to 04:30)
Number of subjects: 392
Study: 20473057

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 25 mg eq.
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq.
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (all doses combined)
Number of subjects: 652
Study: 18025444

Group type: EXPERIMENTAL
Intervention: Lumbar support group
Number of subjects: 360

Group type: COMPARATOR
Intervention: Short course only (Control)
Number of subjects: 360
Study: 15467555

Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 923

Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 923
Study: 11460520

Group type: EXPERIMENTAL
Intervention: Factor XIII
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9710647

Group type: EXPERIMENTAL
Intervention: Telemedicine examination
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 13
Study: 8790560

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) units of recombinant IFN-alpha-2b (rIFN) subcutaneously three times per week for 24 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: 1 x 10(6) units of recombinant IFN-alpha-2b (rIFN) subcutaneously three times per week for 24 weeks
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 3 x 10(6) units of rIFN
Number of subjects: 163
Study: 2691375

Group type: EXPERIMENTAL
Intervention: Extensive surgical resection (quadrantectomy) with axillary dissection and radiotherapy (QUART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QUART technique (quadrantectomy with axillary dissection and intensive radiotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QUART techniques (quadrantectomy and axillary dissection without radiotherapy)
Number of subjects: 0
Study: 781661

Group type: EXPERIMENTAL
Intervention: Fluocinonide ('Metosyn') applied once daily
Number of subjects: 2

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate ('Betnovate') applied twice daily
Number of subjects: 2
Study: 28919200

Group type: EXPERIMENTAL
Intervention: Benralizumab every 8 weeks
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Benralizumab every 4 weeks
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2295
Study: 27555131

Group type: EXPERIMENTAL
Intervention: Ambu Aura‐i
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 65
Study: 24972557

Group type: EXPERIMENTAL
Intervention: Curved scissors
Number of subjects: 155

Group type: COMPARATOR
Intervention: Straight scissors
Number of subjects: 155
Study: 22906738

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNβ-1b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20012179

Group type: EXPERIMENTAL
Intervention: Self-determination theory (SDT) based weight management intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: General health education program (control)
Number of subjects: 239
Study: 18824271

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (EXU; Exubera)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Short-acting subcutaneous (SC) insulin
Number of subjects: 580
Study: 15919435

Group type: EXPERIMENTAL
Intervention: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus + low-dose Mycophenolate Mofetil (750 mg orally twice a day) + steroids
Number of subjects: 30
Study: 12768289

Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15.1 mg, treated once daily orally from 3 days before PRK to 1 month after PRK
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment with LA and GLA)
Number of subjects: 60
Study: 10814990

Group type: EXPERIMENTAL
Intervention: 0.8-fold dose of protamine (Group L)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2.0-fold dose of protamine (Group H)
Number of subjects: 28
Study: 8861577

Group type: EXPERIMENTAL
Intervention: Standardized ultrasound examination
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard X-rays of the shoulder
Number of subjects: 29
Study: 1519637

Group type: EXPERIMENTAL
Intervention: Diltiazem (120, 240, 360, or 480 mg)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day for 2 weeks, 360 mg/day for 2 weeks, and then 540 mg/day for 2 weeks)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 6501124

Group type: EXPERIMENTAL
Intervention: Single dose of 2 g latamoxef (moxalactam)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Three doses of latamoxef (moxalactam)
Number of subjects: 20
Study: 30277420

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia/β-alanine (HB)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: β-alanine (BA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normoxia/placebo (NP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normobaric hypoxia/placebo (HP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normoxia/β-alanine (NB)
Number of subjects: 38
Study: 30281397

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation (MOP) with fixed appliance (Gemini 3M) every 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with identical brackets without MOP
Number of subjects: 60
Study: 26936194

Group type: EXPERIMENTAL
Intervention: Comprehensive care
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 281
Study: 25233856

Group type: EXPERIMENTAL
Intervention: TRK‐100STP 60 μg b.i.d.
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: TRK‐100STP 120 μg b.i.d.
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 22336172

Group type: EXPERIMENTAL
Intervention: High intake of rye bread (99 g/d to 198 g/d)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High intake of rye bread with plant sterols
Number of subjects: 63
Study: 21163113

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg to 120 mg once daily
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg once daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 215
Study: 18274211

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention for 12 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 147
Study: 16245485

Group type: EXPERIMENTAL
Intervention: Pointing movements with 8 stimulus sizes (2.5 cm to 20 cm) and 32 durations (0.2 s to 1.75 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Writing movements with 8 stimulus sizes (2.5 cm to 20 cm) and 32 durations (0.2 s to 1.75 s)
Number of subjects: 0
Study: 12398872

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cyclosporine, azathioprine and prednisone (Control)
Number of subjects: 36
Study: 10464707

Group type: EXPERIMENTAL
Intervention: Group A: IFN (alpha Interferon‐1,000,000 U/d), Cyclosporine A (CSA‐1 mg/kg/d intravenous) for 28 days, and GM‐CSF (250/m2/d) until engraftment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B: CSA (1 mg/kg/d intravenous) and GM‐CSF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group C: CSA (1 mg/kg/d orally) and GM‐CSF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group D: only GM‐CSF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients who developed GVHD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients without GVHD
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patients with multiple myeloma (MM)
Number of subjects: 80
Study: 7717013

Group type: EXPERIMENTAL
Intervention: Diltiazem (3 x 60 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metoprolol (3 x 50 mg daily)
Number of subjects: 24
Study: 3437274

Group type: EXPERIMENTAL
Intervention: Prosocial videogame (played singly)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aggressive videogame (played singly)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aggressive videogame (played competitively)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Prosocial videogame (played cooperatively)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 160
Study: 29924771

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy to achieve LDLC level less than 1.8 mmol/l
Number of subjects: 82

Group type: COMPARATOR
Intervention: Therapy to achieve LDLC level below 2.6 mmol/l
Number of subjects: 82
Study: 27145207

Group type: EXPERIMENTAL
Intervention: Soy food supplementation (50 mg isoflavones or 15 g soy protein in the form of tofu)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Very low‐fat diet (11.3% of total energy)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 57
Study: 24959516

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic health education (BHE)
Number of subjects: 40
Study: 22480863

Group type: EXPERIMENTAL
Intervention: 40-min preoperative home rehabilitation education program 4 weeks prior to TKA
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (no preoperative program)
Number of subjects: 243
Study: 20860662

Group type: EXPERIMENTAL
Intervention: VS411-2 formulation (didanosine 400 mg and hydroxyurea 600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available ddI (Videx EC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea (Hydrea)
Number of subjects: 0
Study: 18082885

Group type: EXPERIMENTAL
Intervention: Orbital radiation treatment
Number of subjects: 100
Study: 19958855

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 8800

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 8800
Study: 16226178

Group type: EXPERIMENTAL
Intervention: Fluorescent indocyanine green (ICG) angiography
Number of subjects: 120
Study: 11688001

Group type: EXPERIMENTAL
Intervention: Recombinant human hemoglobin (rHb1.1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study: 9230329

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg twice daily for 10 days)
Number of subjects: 164
Study: 8233265

Group type: EXPERIMENTAL
Intervention: Esterified estrogens plus methyltestosterone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Esterified estrogens alone
Number of subjects: 26
Study: 3112672

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Erythromycin (base)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Erythromycin (stearate)
Number of subjects: 315

Group type: COMPARATOR
Intervention: No peritreatment antibiotics (from previous study)
Number of subjects: 315
Study: 11579306

Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone (double-drug therapy)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Number of subjects: 350
Study: 30914089

Group type: EXPERIMENTAL
Intervention: Cognitive intervention training (playing electronic musical keyboard, learning simple Spanish, clock‐drawing, psychological intervention) for 2 months
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cognitive intervention training
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no cognitive training)
Number of subjects: 133
Study: 30333302

Group type: EXPERIMENTAL
Intervention: Kisspeptin
Number of subjects: 0
Study: 26488615

Group type: EXPERIMENTAL
Intervention: Speed instructions
Number of subjects: 35

Group type: COMPARATOR
Intervention: Accuracy instructions
Number of subjects: 35
Study: 24752880

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22248502

Group type: EXPERIMENTAL
Intervention: BEET (140 ml/d of concentrated beetroot juice; 8 mmol/d nitrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLAC (nitrate-depleted beetroot juice)
Number of subjects: 12
Study: 20215360

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU)
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in boys
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in girls
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Combined estimate of neonatal vitamin A supplementation on mortality
Number of subjects: 1717
Study: 17365790

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 24
Study: 15734603

Group type: COMPARATOR
Intervention: Tibolone 1.25 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tibolone 5.0 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tibolone 0.625 mg
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tibolone (all doses)
Number of subjects: 317
Study: 11781274

Group type: EXPERIMENTAL
Intervention: CNI-1493 (8 mg/m2 daily for 12 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CNI-1493 (25 mg/m2 daily for 12 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CNI-1493 (both dosages)
Number of subjects: 12
Study: 9579005

Group type: EXPERIMENTAL
Intervention: Nicotine-containing gum (NCG)
Number of subjects: 299
Study: 7815681

Group type: EXPERIMENTAL
Intervention: Mini-liposuction procedure
Number of subjects: 15
Study: 2682877

Group type: EXPERIMENTAL
Intervention: Home continuous intravenous infusion chemotherapy (CVI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inpatient continuous intravenous infusion chemotherapy (CVI)
Number of subjects: 22
Study: 5354851

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate plus succinic acid
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate plus ascorbic acid
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ferrous sulphate with ascorbic acid and succinic acid
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ferrous fumarate (tablets)
Number of subjects: 5
Study: 30376388

Group type: EXPERIMENTAL
Intervention: Massage (20 min, twice a week for 12 weeks)
Number of subjects: 36
Study: 28439734

Group type: EXPERIMENTAL
Intervention: Early reperfusion (PCI within 12 hours)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Late reperfusion (PCI between 12 and 48 hours)
Number of subjects: 788
Study: 25483979

Group type: EXPERIMENTAL
Intervention: 5-day discontinuation of statin treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Continuation of statin treatment
Number of subjects: 34
Study: 24085590

Group type: EXPERIMENTAL
Intervention: Tizanidine nasal spray (32.73 mg/mL) at doses of 2 mg and 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tizanidine nasal spray (16.36 mg/mL) at a dose of 1 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tizanidine oral tablets (4 mg)
Number of subjects: 12
Study: 21943084

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy self management programme administered by a clinical psychologist over six consecutive weekly sessions (2 hours each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (atypical analgesia and local anaesthetic injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy self management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0